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Abstract. 
 
Recent studies have indicated a role for ca-
veolin in regulating cholesterol-dependent signaling
events. In the present study we have analyzed the role
of caveolins in intracellular cholesterol cycling using a
dominant negative caveolin mutant. The mutant caveo-
 
lin protein, cav-3
 
DGV
 
, specifically associates with the
membrane surrounding large lipid droplets. These
structures contain neutral lipids, and are accessed by ca-
veolin 1–3 upon overexpression. Fluorescence, elec-
tron, and video microscopy observations are consistent
with formation of the membrane-enclosed lipid rich
structures by maturation of subdomains of the ER. The
caveolin mutant causes the intracellular accumulation
of free cholesterol (FC) in late endosomes, a decrease
in surface cholesterol and a decrease in cholesterol ef-
flux and synthesis. The amphiphile U18666A acts syner-
gistically with cav
 
DGV
 
 to increase intracellular accumu-
lation of FC. Incubation of cells with oleic acid induces
a significant accumulation of full-length caveolins in the
enlarged lipid droplets. We conclude that caveolin can
associate with the membrane surrounding lipid droplets
and is a key component involved in intracellular choles-
terol balance and lipid transport in fibroblasts.
Key words: caveolin • caveolae • cholesterol • lipid
droplets • endoplasmic reticulum 
 
Introduction
 
Traditionally, caveolae have been defined morphologi-
cally as bulb-shaped structures on the cell surface, and
biochemically as cholesterol- and caveolin-rich domains
(for a recent review see Kurzchalia and Parton, 1999).
Over the last few years, it has become evident that the
link between caveolins and cholesterol is not restricted to
the simple spatial colocalization in liquid-ordered phases
on the plasma membrane. Caveolins regulate the intracel-
lular transport of cholesterol in a complex process involv-
ing caveolae, the ER, and the Golgi complex (Smart et al.,
1996; Scheiffele et al., 1998). Whereas plasma membrane
caveolae are the final or the first step of that cycle (Smart
et al., 1994; Babitt et al., 1997), intracellular caveolin traf-
ficking could be the key to understanding cellular choles-
terol homeostasis.
Accumulating evidence suggests that caveolins may act as
cholesterol sensors, and therefore as modulators of a wide
range of cellular functions. Cav-1 expression is regulated at
 
the transcriptional level by cholesterol (Bist et al., 1997). Nie-
mann-Pick disease type C (NPC)
 
1
 
 is an autosomal recessive
lipid storage disorder, caused by mutations in the NPC1
protein and characterized by the accumulation of unesteri-
fied cholesterol in late endosomal compartments (for a re-
view see Liscum, 2000). Cav-1 protein levels are increased
several-fold in NPC1 heterozygotes, but homozygotes show
only slightly increased cav-1 levels despite greatly increased
unesterified cholesterol levels (Garver et al., 1997). This
suggests that NPC1 may act indirectly as a regulatory factor
of cav-1 expression. NPC1 is a multispanning membrane
protein that contains a sterol-sensing domain that is homol-
ogous to the transmembrane domain of sterol-regulatory el-
ement-binding protein (SREBP)-cleavage activating pro-
tein (SCAP) (Brown and Goldstein, 1997). SCAP responds
to low cholesterol levels by activating SREBP cleavage
from the membranes of the ER (Hua et al., 1996). In human
skin fibroblasts, SREBP-1 was described as a transcrip-
tional inhibitor of caveolin gene expression (Bist et al.,
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Abbreviations used in this paper: 
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membrane; SCAP, SREBP-cleavage activating protein; SREBP, sterol-
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1997). Intriguingly, there is also homology between NPC1
and the sterol sensing domain of Patched, the membrane re-
ceptor for Sonic hedgehog (Marigo et al., 1996), which itself
contains a cholesterol moiety (Porter et al., 1996).
Caveolin and cholesterol have been linked to numerous
signaling processes (see for a recent review Kurzchalia and
Parton, 1999), but is it is still unclear how the cholesterol/
caveolin cycle affects these processes. Cholesterol is syn-
thesized in the ER of all nucleated cells and transported to
the plasma membrane (PM), in part by a nonvesicular
pathway (Kaplan and Simoni, 1985; Urbani and Simoni,
1990). Cells also take up cholesterol by receptor-mediated
endocytosis of LDL, which is transported through the en-
docytic compartment to late endosomes. From late endo-
somes cholesterol is transferred to the PM or to the ER
(Spillane et al., 1995; Underwood et al., 1998). Moreover,
cholesterol can be converted to cholesteryl ester by the
ER resident enzyme acyl-CoA/cholesterol acyltransferase
(ACAT) to form the ester storage pool of the cell. Plasma
membrane caveolae have been proposed as ports for the
efflux of free cholesterol (FC), de novo synthesized or
LDL-derived, to extracellular acceptors and possibly to
the rest of the plasma membrane (Smart et al., 1996; Field-
ing and Fielding, 1997). In addition, in steroidogenic tis-
sues and liver or in transfected CHO cells, the caveolae
resident scavenger receptor SR-B1 mediates not only the
efflux of FC to HDL but the selective uptake of HDL-cho-
lesteryl esters (Babitt et al., 1997). How cholesterol dis-
tributes to other intracellular membranes remains un-
known, although the existence of lipid rafts not only on the
plasma membrane but in some intracellular membranes
has been suggested. For instance, it was shown that a cho-
lesterol-dependent sorting of GPI-anchored proteins oc-
curs in recycling endosomes (Mayor et al., 1998) which
contain some raft components (Gagescu et al., 2000).
The intracellular trafficking itinerary of caveolin is still
controversial. Conformational changes of the caveolin
protein complicate the interpretation of its localization in
different cellular pools (Dupree et al., 1993; Luetterforst
et al., 1999). Cav-1 is a fatty acid and cholesterol-binding
protein (Murata et al., 1995; Trigatti et al., 1999). More-
over, cav-1 and 2 form homo- and heterooligomers in a
process promoted by cholesterol (Murata et al., 1995). Ca-
veolins have been considered as integral “hairpin”-like
proteins with an intramembrane region of 33 amino acids,
although they have been also described associated with li-
poprotein particles in the secretory pathway of exocrine
cells (Liu et al., 1999) or in cytosolic complexes, together
with cholesterol and HSP56 (Uittenbogaard et al., 1998).
Caveolin has been suggested to transport cholesterol from
the ER to the plasma membrane (Smart et al., 1996) in a
process, at least in part, mediated by a cytosolic pool of
caveolin associated with chaperone complexes (Uitten-
bogaard and Smart, 2000). Cav-1 and -2 are present in ves-
icles carrying sphingolipids and GPI-anchored proteins
from the trans Golgi network to the plasma membrane of
epithelial cells (Scheiffele et al., 1998). In addition, oxida-
tion of cholesterol by cholesterol oxidase induces caveolin
redistribution from the plasma membrane to the ER/Golgi
complex (Smart et al., 1994). The early exocytic pathway
also has been recognized as an intermediate on the caveo-
lin cycling pathway and a putative cis-Golgi targeting mo-
 
tif was identified in the COOH terminus of the protein
(Luetterforst et al., 1999).
In the present study we have investigated the role of ca-
veolins in regulating intracellullar cholesterol homeostasis
using a caveolin dominant mutant with two interesting
properties; firstly, it can not reach the plasma membrane
but accumulates in an intracellular compartment, and sec-
ondly, it inhibits the signal transduced by H-Ras by modi-
fying cholesterol distribution. Our results show that this
mutant protein behaves as in integral membrane protein
and associates with the limiting membrane of lipid drop-
lets. The mutant protein perturbs lipid transport resulting
in changes in FC distribution.
 
Materials and Methods
 
Plasmids 
 
YFP, GFP, and HA-tagged cav
 
DGV 
 
(residues 54–151) and the equivalents
for cav-1, HA-tagged cav-1
 
DGI
 
 (residues 82–178) and cav-2, HA-tagged
cav-2
 
DKV
 
 (residues 67–162), HA-tagged cav
 
LLS
 
 (residues 75–151) and full-
length YFP and GFP-tagged cav-3 were generated as described previously
(Luetterforst et al., 1999). Full-length cav-1 VSVG and full-length cav-2
myc have been previously described (Dupree et al., 1993; Scheiffele et al.,
1998). CFP-tagged ER marker was purchased from CLONTECH. Myc-
tagged sialotransferase was provided by Dr. Tommy Nilsson (EMBL,
Heidelberg, Germany). Mouse NPC1 was provided by Dr. Jean Wilson
(University of Arizona, Tucson, AZ).
 
Cell Culture, Antibodies, and Reagents 
 
Baby hamster kidney cells (BHK) were maintained in DME with 10%
vol/vol FCS supplemented with 2 mM 
 
L
 
-glutamine. Cells were transfected
using lipofectamine Plus (GIBCO BRL) according to the manufacturer’s
instructions. Quantitation of expression using cav-1 VSVG-transfected
cells and a polyclonal anticaveolin antibody suggested that transfected
protein was present at levels 3–4 times higher than endogenous levels
(data not shown).
 
 
 
In some experiments, before and/or after transfection
cells were treated with 4.5 
 
m
 
g/ml of U18666A (from a stock solution in wa-
ter stored at 
 
2
 
20
 
8
 
C for less than 3 months).
 
 
 
In some experiments, cells
were preincubated for 16 h before transfection in a medium containing 50
 
m
 
g/ml of oleic acid (Calbiochem) conjugated with fatty acid free BSA
(Calbiochem) and incubated in the same medium for the time of the trans-
fection as described previously (Brasaemle et al., 1997).
Primary antibodies used in this work are summarized in Table I. Gold-
conjugated protein A was provided by Dr. J. Slot (University of Utrecht,
Utrecht, The Netherlands). Fluorescein, Cy3, and gold-conjugated sec-
ondary antibodies were from Jackson ImmunoResearch. HRP-conjugated
secondary antibodies were from Zymed Laboratories.
3
 
b
 
-(2-diethylaminoethoxy)-androstenone (U18666A) is from BIO-
MOL Research Laboratories. 4
 
9
 
,6-diamidino-2-phenylindole, dihydro-
chloride (DAPI), lysoTracker, and Nile red were from Molecular Probes.
Cycloheximide, Triton X-100, filipin, brefeldin A (BFA), nocodazole and
cytochalasin D were purchased from Sigma Chemical Co. 4[
 
14
 
C]choles-
terol (specific activity, 50.0 Ci/mmol) was from Amersham Pharmacia
Biotech. Human serum was from a healthy volunteer.
 
Immunofluorescence, Electron Microscopy, and
Video Microscopy 
 
Immunofluorescence. 
 
Cells were prepared for immunofluorescence mi-
croscopy as described previously (Luetterforst et al., 1999). In extraction
experiments, confluent cells were incubated by immersion in 300 
 
m
 
l of
cold 10 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100,
and a mixture of protease inhibitors for 3 min on ice, washed in cold PBS,
and were then fixed for 10 min in cold 4% PFA and an additional 30 min
at room temperature and finally processed for immunofluorescence or
electron microscopy. In other experiments, cells were pretreated before
fixation with 5 
 
m
 
g/
 
m
 
l of BFA for 4 h, 100 
 
m
 
M of chloroquine for 2 h, 1.6
 
m
 
M nocodazole for 1 h, 10 
 
m
 
M cytochalasin D for 1 h or with 10 
 
m
 
g/ml cy-
cloheximide for 24 h.
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GM1 Internalization Assay.  
 
Transfected cells were rinsed in Air me-
dium (10% FCS, Hanks minimal essential media (GIBCO), 0.75 mg/ml
sodium bicarbonate, 10 mM Hepes, pH 7.4) and incubated in the same
medium containing 10 mg/ml of sialoganglioside-GM1 (Sigma Chemical
Co) at 37
 
8
 
C for 2 h. After fixing the cells with 4% PFA, coverslips were in-
cubated for 30 min in a blocking solution (0.2% BSA, 0.2% fish skin gela-
tin diluted in PBS) containing 1 
 
m
 
g/ml of cholera toxin FITC conjugated
(Sigma Chemical Co).
 
Nile Red Staining. 
 
Cells were transfected by electroporation (300 V, 125
 
m
 
F at 25
 
8
 
C) and plated on coverslips and labeled with mAbs to HA, fol-
lowed by Cy3-conjugated secondary antibodies, and finally mounted in
mowiol containing Nile red (1:1,000 from a saturated stock solution in ace-
tone). Transfected cells were selected for the presence of rings in the red
channel and the corresponding image in the green channel was captured.
Then, the samples were exposed for 30 s in the red channel (to quench the
presence of lipid dye in the red channel) before the corresponding image
was captured. To quantitate the relative amounts of Nile red labeling in
transfected and nontransfected cells, fields were selected that contained
an example of each. Using NIH image software, the mean pixel intensity
per unit area of one of each cell type was assayed. The nontransfected con-
trol cell was then given a base value of 1.00 and the relative pixel intensity
of the transfected cell was expressed as a factor. This was repeated in 14
different random fields allowing an average difference to be calculated.
 
Filipin Staining.  
 
Filipin staining was performed as outlined previously
(Carozi et al., 2000).
 
Preembedding Labeling of Triton X-100 Extracted Cells. 
 
GFP-tagged
cav
 
DGV
 
-transfected cells were extracted with Triton X-100 as described,
and were then fixed with 4% PFA, 0.02% glutaraldehyde in KoAc for 10
min, quenched, and blocked as above. Cells were labeled with antibodies
for GFP diluted in blocking solution for 1 h, extensively washed with PBS
and were then incubated with gold-conjugated protein A for 2 h. Then the
cells were washed for 30 min in PBS and fixed with 1% glutaraldehyde in
100 mM cacodylate buffer for 1 h and processed for Epon embedding in
the dish by standard procedures as described previously (Parton, 1994).
Sections were cut parallel to the culture dish.
 
Lowicryl and Frozen Sectioning.  
 
BHK cells were embedded in Lowicryl
HM23 resin after fixation in 1% glutaraldehyde in 100 mM cacodylate
buffer. They were then processed exactly as described previously (Parton,
1994) with the modification that the cells were embedded in Lowicryl
HM23 rather than HM20. Frozen sections were prepared as described
previously (Luetterforst et al., 1999). Frozen and Lowicryl sections were
labeled according to standard techniques (Parton, 1994).
 
Time-lapse Video Microscopy. 
 
BHK cells were transfected with GFP-
tagged cav
 
DGV
 
. After 18 h the growth media was replaced with Air me-
dium. The cells were observed in an Olympus BX60 microscope with a
60
 
3
 
 water immersion lens, and the images were captured using IP Lab
software with a CCD camera (Hamamatsu). Images were captured au-
tomatically at intervals ranging from 10 s to 1 min. Dual color movies
were made with the addition of lysoTracker to a final concentration of
50 nM in Air media in 35-mm dishes of BHK cells transfected with
GFP-tagged cav
 
DGV
 
 for 24 h. Then, the automatic capture was set at 20 s
intervals. After the automatic capture in the first channel, another im-
 
age was immediately captured in the second channel with a delay of 2 s.
IP Lab software was then used to produce composite images, which
could then be animated. All images were further processed using
Adobe Photoshop 5.0 to enhance contrast and adjust the apparent in-
tensity in the dual color movie.
 
Cell Fractionation and Western Blotting 
 
Confluent 10-cm dishes of transfected BHK were washed twice with cold
PBS before being scraped into ice-cold 10 mM Tris, pH 7.5, 150 mM NaCl,
5 mM EDTA, and a mixture of protease inhibitors. Cells were homoge-
nized by passing through a 22-gauge needle 25 times at 4
 
8
 
C. In some exper-
iments, cells were scraped in 0.5 M Na
 
2
 
Co
 
3
 
, pH 11.5, and in this case ho-
mogenized by passing them through a 22-gauge needle 10 times at 4
 
8
 
C. In
other experiments the homogenization buffer contained 1% Triton X-100
and the cells were homogenized by passing through a 22-gauge needle 10
times at 4
 
8
 
C. Nuclei and unbroken cells were removed by centrifugation at
5,000 rpm in a TLS-55 rotor (Beckman) for 5 min at 4
 
8
 
C. The resulting su-
pernatant was centrifuged at 75,000 rpm in a TLA-100 rotor (Beckman) to
separate membranes (p75) from soluble proteins (sol). Finally, the pellets
were resuspended in homogenization buffer and sonicated to make them
soluble. Fractions were stored at 
 
2
 
20
 
8
 
C before processing. Western blot-
ting was performed as described previously (Pol et al., 1999). Protein was
quantified by BCA Protein Reagent Assay kit (Pierce Chemical Co.).
 
Cholesterol Efflux and Biosynthesis Analysis 
 
Cos-1 cells were grown in DME supplemented with 10% FBS and 100 U/ml
penicillin and 100 
 
m
 
g/ml streptomycin. Cells were seeded in 24-well plates
or 35-mm plates for 20 h before transfection in COS-1 medium. The cells
at 
 
z
 
70% confluency were transfected with 1 
 
m
 
g of cav
 
DGV
 
 HA in pCB6 or
vector alone with Fugene-6 according to the manufacturer’s instructions. 3 h
after transfection the medium was replaced by COS-medium containing
[
 
14
 
C]cholesterol (100 nCi/ml) and incubated for further 45 h. Then cells
were processed by analysis of cholesterol biosynthesis as previously de-
scribed (Heino et al., 2000) or cholesterol efflux. To quantify cholesterol
efflux cells were then incubated for 3 h in the absence of label, washed
twice with PBS, and once with serum-free DME, and efflux was carried
out in 500 
 
m
 
l of DME containing 20% human serum for 2 h. The medium
was collected and cells were recovered by dissolving in 0.2 M NaOH. Ali-
quots of the cells and medium were analyzed by liquid-scintillation count-
ing to determine the [
 
14
 
C]cholesterol content.
 
Online Supplemental Material 
 
Online supplemental materials can be found at http://www.jcb.org/cgi/
content/full/152/5/1057/DC1. Time-lapse video microscopy: Video 1 corre-
sponds to Fig. 4 a. Cav
 
DGV
 
 vesicles are immobile and nonacidic vesicles
(real time 28 min). Video 2 corresponds to Fig. 4 b. Cav
 
DGV
 
 transits the tu-
bules of the ER and accumulates in a stable compartment (real time 100
min). Video 3, corresponds to Fig. 4 c. High magnification of the CDV
compartment formation (real time 125 min).
 
Table I. Antibodies Used in This Work
 
Antibody Specificity Reference
 
HA Mo Prof. David James (University of Queensland, Queensland, Australia)
HA Rb Dr. Tommy Nilsson (EMBL, Heidelberg, Germany)
VSVG Rb Dr. Tommy Nilsson (EMBL, Heidelberg, Germany)
myc Rb Dr. Tommy Nilsson (EMBL, Heidelberg, Germany)
GFP Rb Prof. David James (University of Queensland, Queensland, Australia)
Caveolin 1 Rb Transduction Laboratories (C13630)
Caveolin 1 Mo Transduction Laboratories (C37120)
p23 Rb Prof. Jean Gruenberg (University of Geneva, Geneva, Switzerland) (Rojo et al., 1997)
KDEL-receptor Rb Dr. Hans-Peter Hauri (Biozentrum, Basel, Switzerland) (Griffiths et al., 1994)
KX5 Rb Dr. Steven Fuller (EMBL, Heidelberg, Germany)
PDI (KDDD) Rb Dr. Steven Fuller (EMBL, Heidelberg, Germany)
SKL Rb Zymed Laboratories (71-8400)
NPC1 Rb Dr. Jean Wilson (University of Arizona, Tucson, AZ)
Sec61 Rb Dr. Jean-Pierre Gorvel (CIMR, Marseille, France)
LBPA (6C4) Mo Prof. Jean Gruenberg (University of Geneva, Geneva, Switzerland) (Kobayashi et al., 1998)
Tubulin Mo Sigma Chemical Co. (T9026)
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Figure 1. CavDGV is targeted to the membrane of intracellular vesicular structures. a, BHK cells were transfected with HA-tagged cav-3DGV
for 24 h and were then labeled with antibodies to HA tag, followed by specific Cy3-conjugated secondary antibodies. CavDGV mainly located
in enlarged intracellular rings, and some protein was detected in the tubular elements of the ER (see Fig. 2) and in the perinuclear region (ar-
rows and g and h). b, BHK cells were transfected with HA-tagged cavDGV for 24 h and were then treated with 5 mg/ml of cycloheximide for an
additional 24 h. After blocking of protein synthesis, the truncated protein was exclusively detected in very enlarged intracellular vesicles (ar-
rows). c, BHK cells were transfected with GFP-tagged cavDGV and frozen sections were processed for immunoelectron microscopy using
anti-GFP antibodies, followed by protein A–gold. The mutant protein was detected enriched on the membrane of electron-lucent vesicles of
300–500-nm diam, often surrounded by intermediate filaments (arrows). d and e, Lowicryl sections (of freeze-substituted/low temperature
embedded sections) of GFP-tagged cavDGV-transfected cells labeled with antibodies to GFP followed by protein A–gold. CavDGV-containing
vesicles (CDV) comprise a membrane bilayer (see arrows in d and e) surrounding a putative lipid-filled area. f, Epon sections showing a mor-
phologically similar structure connected to tubular elements possibly corresponding to the ER (arrow and arrowhead), which were frequently
observed in nontransfected cells. The typical morphology of lipid-filled body enclosed by a bilayer structure (see insert) is readily observed in
epon sections. g, BHK cells were cotransfected with myc-tagged sialotransferase (a specific marker for trans Golgi) and HA-tagged cavDGV
and the distribution of the proteins studied by immunofluorescence by means of antitag specific antibodies. The distribution of sialotrans-
ferase (green) and cavDGV (red) clearly overlapped in the Golgi area, however CDV rings did not contain the Golgi marker. h, HA-tagged
cavDGV-transfected cells were label with an mAb to cav-1 (which exclusively recognizes the Golgi complex conformation of cav-1) and a poly-
clonal antibody to HA-tag. When cavDGV (red) accumulated in the Golgi region, the truncated protein clearly colocalized with the Golgi com-
plex-associated pool of endogenous cav-1 (green). i and l, HA-tagged cavDGV-transfected cells were labeled with polyclonal antibodies to the
peroxisome marker SKL (l) or the late endosome marker, lysobisphosphatidic acid (h) and with an mAb to the HA-tag. The endosome and
peroxisome markers (green) were excluded from the CDV compartment (red). j, CavDGV-transfected cells were incubated for 2 h at 378C with
10 mg/ml of GM1 to allow insertion of the ganglioside into the plasma membrane and internalization. GM1, detected by using 1 mg/ml of Chol-
era toxin–FITC, was completely excluded from the CDV compartment (red). k, BHK cells were cotransfected with Niemann-Pick C1 protein
and cavDGV for 24 h and were then labeled with a polyclonal antibody to NPC1 and the mAb to the HA tag. Transfected NPC1 (green) does
not colocalize with the CDV vesicles (red). Bars: (a, b, and g–l) 5 mm; (c–f) 100 nm.
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Results
 
Cav
 
DGV
 
 Is Targeted to the Limiting Membrane of 
Intracellular Spherical Structures, but Not to the 
Plasma Membrane
 
To examine the intracellular itinerary of caveolin and its
role in cholesterol homeostasis, we studied the intracellu-
lar location of the cav
 
DGV
 
 mutant, a truncated protein that
acts as a dominant negative inhibitory mutant through an
effect on cholesterol. Cav
 
DGV
 
 is a deletion of cav-3, which
lacks the first 53 residues of the protein but contains an in-
tact scaffolding domain. This mutant protein localizes to an
apparently novel nonendocytic intracellular compartment.
COOH-terminally HA-tagged cav
 
DGV
 
 was expressed in
BHK cells and its distribution analyzed by immunofluo-
rescence microscopy. The protein showed a characteristic
staining of large intracellular rings (Fig. 1, a and b). Identi-
cal results were obtained when NH
 
2
 
-terminally GFP or
COOH-terminally YFP-tagged cav
 
DGV
 
 was expressed (see
below). Often rings of different sizes and complexes of two
or more vesicles could be observed (Fig. 1 a). In addition,
some labeling was observed in tubular elements, charac-
teristic of the ER (see later) and in the Golgi region (Fig. 1
a, arrow; also see Luetterforst et al., 1999),
 
 
 
but after cyclo-
heximide treatment only the ring-like staining was ob-
served in very enlarged vesicles (Fig. 1 b, arrows).
 
 
 
This
strongly suggests that the steady state distribution of this
mutant protein is the ring-like structures. Consistent with
previous results (Roy et al., 1999), cav
 
DGV 
 
was not de-
tected on the plasma membrane, even using the YFP or
GFP-tagged construct, suggesting that the lack of surface
labeling is not due to inaccessibility of epitopes.
To further characterize the properties and origin of the
cav
 
DGV
 
 compartment, we performed electron microscopy
on cav
 
DGV
 
–GFP-expressing cells. Frozen sections provided
high labeling efficiency (Fig. 1 c) and showed labeling for
the mutant protein surrounding an electron lucent area,
reminiscent of a lipid droplet. Cav
 
DGV
 
 containing vesicles
were often surrounded by intermediate filaments (see ar-
rows in Figs. 1 c and 5 d). However, the frozen sections did
not provide good membrane preservation in the area of
the cav
 
DGV
 
-labeled structures. We therefore employed a
freeze-substitution/low temperature embedding approach
that has been optimized for retention and high resolution
localization of lipids (van Genderen et al., 1991; Voorhout
et al., 1991; Parton, 1994). The HM23 lowicryl sections of
cav
 
DGV
 
-transfected cells were labeled with antibodies to
GFP, followed by protein A-gold. Labeling was observed
on large spherical electron-lucent structures of 300–500-
nm diam (Fig. 1, d and e) which were enclosed by a clearly
defined membrane (arrows). The morphology of the la-
beled elements suggested that the cav
 
DGV
 
 mutant is specifi-
cally targeted to the limiting membrane of a membrane-
enclosed compartment containing lipids. Structures with
identical morphology were observed in nontransfected
cells (Fig. 1 f). Those structures were often closely associ-
ated with tubular elements (Fig. 1 f, arrow and arrowhead)
presumably corresponding to the ER.
 
Cav
 
DGV 
 
Accumulates in a Subcompartment of the ER
 
Our previous studies (Roy et al., 1999)
 
 
 
suggested that the
cav
 
DGV
 
 vesicles (here operationally abbreviated to CDVs
for Cav-DGV–labeled vesicles) lack endosomal markers,
but the molecular nature and origin of these vesicles was
unknown. Therefore, we carried out a series of labeling
experiments to examine the nature of this compartment.
The Golgi complex, late endosomes, and the ER have all
been described as intermediate steps in the intracellular
trafficking of cholesterol and caveolin has been described
previously in the Golgi network (Kurzchalia et al., 1992).
Epitope-tagged sialotransferase, a specific marker of the
trans-Golgi, was cotransfected with cav
 
DGV
 
 in BHK cells.
Although the markers overlapped in the Golgi region, the
proteins did not colocalize in the characteristic CDVs (Fig.
Figure 2. CDV rings contain markers for the ER. a–d, BHK cells were transfected with cavDGV for 24 h, and were then labeled with a
polyclonal antibody to PDI (a marker for the ER) and an mAb to the HA tag. PDI (green) was located in the reticular network charac-
teristic of the ER (b) and in some vesicular structures that colocalized to some extent with CDV rings (red) (b and c, arrows). The colo-
calization between both proteins was corroborated in frozen sections of cavDGV-transfected cells (d) labeled with the same antibodies,
followed by anti-rabbit antibodies conjugated to 15-nm gold (arrows) and anti-mouse antibodies conjugated to 5-nm gold (arrowheads).
e–g, BHK cells were double transfected with CFP-tagged ER marker and HA-tagged cavDGV. The cells were labeled with a polyclonal
antibody to GFP (to increase the signal) and the mAb to HA tag (e). Clear colocalization could be observed between some of the CDV
rings (red) and the ER marker (green) (f and g, arrows). Bars: (d) 100 nm; (a–e) 5 mm.
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1 g).
 
 
 
The same colocalization was observed when cav
 
DGV
 
-
transfected cells were label with an mAb to cav-1 (which
exclusively recognizes the Golgi complex
 
 
 
conformation of
cav-1, but not cav
 
DGV
 
). When cav
 
DGV
 
 accumulated in the
Golgi region, the truncated protein clearly colocalized
with the Golgi
 
 
 
complex-associated pool of endogenous
cav-1 (Fig. 1 h). In view of the lipidic nature of the internal
core of the CDVs, as visualized by electron microscopy,
we examined the distribution of lysobisphosphatidic acid
(LBPA), a lipid that is highly enriched in late endosomes
(Kobayashi et al., 1998), and the ganglioside GM1, which
was incorporated into the plasma membrane and internal-
ized for 2 h at 37
 
8
 
C to label the endocytic system. Neither
marker colocalized with the caveolin mutant (Fig. 1, i and
j). NPC1, which plays a vital role in cholesterol transport,
has been suggested to associate with both endosomal and
nonendosomal compartments (Garver et al., 2000). How-
ever, NPC1 was also excluded from the CDVs (Fig. 1 k).
We then carried out a series of colocalization studies of
cav
 
DGV
 
 with markers of other compartments, including a
peroxisomal marker (SKL, Fig. 1 l) and four ER specific
markers (Sec61, Kx5, KDEL-R, and PDI). Of these mark-
ers, only two, PDI (Fig. 2 a, and arrows in b and c) and
KDEL-R (not shown), colocalized to some extent with
DGV vesicles, suggesting that the vesicles were derived
from the ER. Colocalization between DGV and PDI was
confirmed by electron microscopy studies in frozen sec-
tions of cav
 
DGV
 
-transfected cells (Fig. 2 d). To examine
this further, BHK cells were cotransfected with cav
 
DGV
 
and a fluorescently tagged ER marker. Clear colocaliza-
tion was observed between some of the ring-like CDVs
 
and the ER marker (Fig. 2 e, and arrows in f and g). We
conclude that although cav
 
DGV
 
 can transit the Golgi net-
work and the tubular elements of the ER, the steady state
distribution of the protein is a subcompartment of the ER.
 
The cav
 
DGV 
 
Compartment Is Accessed by all the Known 
Caveolin Family Members 
 
We next
 
 
 
investigated whether the CDVs might be a general
feature of the caveolin cycling pathway by examining
whether full-length caveolins can access this compartment.
Cav
 
DGV
 
 was coexpressed with full-length cav-1, 2, or 3. Full-
length caveolins distributed in a similar manner to endoge-
nous cav-1 and the protein could be detected on the PM, in
the Golgi region of the cells, and showed limited colocaliza-
tion with the cav
 
DGV
 
 mutant protein (not shown). Extensive
colocalization was observed in only a low but significant
percentage of the cavDGV mutant expressing cells (2–5%,
see Fig. 3 a). Full-length caveolins can reach both the PM
and the CDVs but cavDGV is totally excluded from the PM
(see arrowheads in Fig. 3, b and c). Notice that not all the
cav-1 positive rings contained cavDGV (compare Fig. 3, b
and c, arrows), suggesting that the formation of CDV is not
exclusively induced by the presence of the mutant protein
(see also Fig. 1 f). Since cav-1 does not oligomerize with
cav-3, these results suggest that CDVs may be accessed by
wild-type caveolins under physiological conditions.
We then constructed the equivalent truncation mutants
of cav-1 (cav-1DGI) and cav-2 (cav-2DKV). Fig. 3, d and e,
show that cav-1DGI and cav-2DKV accumulated in morpho-
logically identical compartments to cav-3DGV. We then in-
vestigated whether the caveolin scaffolding domain was
Figure 3. The cavDGV pheno-
type is a feature of all caveo-
lin family members. a–c,
BHK cells were cotrans-
fected with full-length VSV-
G–tagged cav-1 and HA-
tagged cavDGV, and after 24 h
were labeled with a rabbit
antibody to VSV-G tag and a
mouse antibody to HA tag.
In a low but significant pro-
portion of transfected cells
(2–5% of transfectants) full-
length cav-1 (green) accumu-
lated in the same intracellular
rings as cavDGV (red). Al-
though in those cells, cav-1
was detected on the PM (a
and c, arrowheads) cavDGV
was totally excluded from the
PM. Some ring-like struc-
tures were strongly labeled
for full-length cav-1 but not
for cavDGV (b and c arrows).
d and e, BHK cells were
transfected with HA-tagged
cav-3DGV equivalent truncation mutants of cav-1 (cav-1DGI, d) and cav-2 (cav-2DKV, e) and the cells labeled with mouse anti-HA tag.
Both equivalent mutants accumulated in morphologically identical rings to cav-3DGV, demonstrating that the CDV compartment is a
general characteristic of all the caveolin family members. f, BHK cells were transfected with HA-tagged cav-3LLS (a cav-3 truncation
lacking the entire NH2-terminal domain up to the putative intramembrane region) and labeled with mouse anti-HA tag. Cav-3LLS accu-
mulated, as cav-3DGV, in CDV-like structures, showing that the caveolin scaffolding domain is not involved in the targeting of the pro-
tein to this compartment. Bars, 5 mm.
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Figure 4. Real-time microscopy. CDV are immobile structures formed by maturation processes in some specific regions of the
ER. a, Living GFP-tagged cavDGV-transfected cells were incubated in a medium containing a marker for acidic compartments,
lysoTracker. Cells expressing GFP-cavDGV were selected under the microscope and the focus was kept constant. Images of both
channels (green/red) with a delay of 10 s between channels were captured over 5 min. The figure shows a selected sequence of 6
consecutive frames (20-s interval between images) representing a total period of 100 s. LysoTracker-labeled vesicles showed a
rapid bidirectional motility (arrows) but cavDGV–GFP positive vesicles showed no significant motility in any axis (arrowheads). b
and c, In an attempt to capture the formation of CDVs, cells were transfected with GFP-tagged cav DGV for 18 h and were then ob-
served by video microscopy. Cells were selected for the presence of forming rings (see arrows in the first panel) and the focus was
kept constant during the entire experiment. Images were captured with a constant interval of 7 min. The figure shows a selected
sequence of 10 consecutive frames representing a total period of 63 min. At time 0, cavDGV–GFP was abundant in the tubular ele-
ments of the ER and in the Golgi area. Progressively the protein is less abundant in the ER and Golgi complex and accumulates in
the forming rings (arrows) to shape well-defined CDV ring-like structures in z60 min. c shows a selected high magnification ex-
ample of CDV formation. The protein can be detected moving in waves along the tubules of the ER (arrowheads) until the forma-
tion of the DGV-containing vacuolar structures (arrows). Bars: (a and b) 5 mm; (c) 1 mm. Supplemental videos are available at
http://www.jcb.org/cgi/content/full/152/5/1057/DC1.
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required for accumulation in this compartment. From Fig.
3 f, it is apparent that removal of the entire NH2 terminus
of cav-3 up to the putative intramembrane region (cav-
3LLS) resulted in labeling of morphologically identical
structures. We conclude that the cavDGV-containing vesi-
cles are accessed by all the caveolin family members and
that the caveolin scaffolding domain is not involved in the
targeting of the protein to this compartment.
CavDGV Vesicles Are Immobile, Nonacidic Vesicles 
whose Formation Is Sensitive to Brefeldin A 
We then tested whether the CDVs were acidic. Lyso-
Tracker, a marker for acidic compartments, did not label
the CDVs. The different properties of the two sets of vesi-
cles was further established by dual color real-time video
microscopy (Fig. 4 a). The lysoTracker-labeled vesicles
showed rapid bidirectional motility (up to 5 mm/min; Fig. 4
a, arrows) consistent with microtubule-based motility of
late endosomes and lysosomes, as described previously. In
contrast, the cavDGV-GFP-labeled vesicles showed no sig-
nificant motility in any axis, remaining focused during the
whole experiment (Fig. 4, arrowheads). Interestingly, the
lysoTracker-positive vesicles showed less motility in re-
gions of the cell close to rings in comparison with those in
the periphery of the cells or in nontransfected cells.
We then used this system to investigate the origin of the
CDVs. Cells were transfected with GFP-tagged cavDGV for
18 h and observed by video microscopy. Fig. 4 b shows a
sequence of ten pictures captured every seven minutes
from a cavDGV expressing cell. As in previous experiments,
the focus of the microscope was kept constant during all
the experiment and all the frames were equally analyzed.
The cells to study were selected for the presence of form-
ing rings (see arrows in the first panel of Fig. 4 b). In cells
selected by these criteria, cavDGV appeared concentrated
in the perinuclear area (around the nucleus and in charac-
teristic tubular elements), presumably corresponding to
the ER. Subsequently, cavDGV progressively accumulated
in the forming structures to finally define a well-shaped
ring in z60–90 min. In accordance with the above results
(Fig. 4 a), the swelling of the compartment occurs without
any appreciable change in the original position of the ring
(see arrows). During the entire sequence, cavDGV could be
observed moving in “waves” along the tubules of the ER
(see arrowheads). In some cases, it was observed that
these tubules fused with preexisting CDVs (see arrow-
heads in Fig. 4 c). After an average of 90 min, the ER-asso-
ciated staining of CDVs became less apparent and few
changes could be observed after that time in relation to
the formation of the rings. Together, these results suggest
that cavDGV transits the tubules of the ER and accumulates
in a nonacidic and stable compartment that originates and
matures in some specific regions of the ER.
Ultrastructural and Biochemical Characterization of 
cavDGV and the cavDGV Vesicles
We further investigated the properties of the CDVs. Trans-
fected BHK cells were incubated in a medium containing 5
mg/ml of BFA for 4 h. BFA treatment induced a dramatic
tubulation of Golgi stacks labeled with p23, however CDV
rings were completely resistant to the treatment once
formed (Fig. 5 a). Then, transfected BHK cells were ex-
tracted, before fixation, at 48C in a buffer containing 1%
Triton X-100. CavDGV distribution was then examined by
immunofluorescence and electron microscopy. CavDGV in
CDVs, but not cavDGV in Golgi or in tubular elements of the
ER, was resistant to preextraction with detergent as judged
by immunofluorescence (Fig. 5 b). When the cells were pre-
treated before extraction with nocodazole (Fig. 5 c) or cy-
tochalasin D (not shown) and were then analyzed by immu-
nofluorescence, CDVs remained unextracted indicating
that resistance to extraction with detergents is not due to
the association of CDVs with elements of the cellular cy-
toskeleton. The same labeling scheme was used for electron
microscopy using anti-GFP antibodies, followed by protein
A-gold to detect the tagged mutant protein. The extraction
procedure removed most of the visible internal membranes
including the nuclear envelope (Fig. 5 e, arrows) and mi-
tochondrial membranes, but the plasma membrane was
largely intact. Labeling for the caveolin mutant was ob-
served on large ring-shaped structures corresponding to the
CDVs (Fig. 5, d and e) often surrounded by intermediate
filaments (Fig. 5 d, arrows). At higher magnification the
gold particles were shown to associate with striking electron
dense filamentous aggregates on the cytoplasmic face of the
CDVs (Fig 5, d and e, arrowheads). The nature of these ag-
gregates remains unknown at the present time. In addition,
no protein was detected on the membrane of vesicles corre-
sponding to the rough ER (Fig. 5 d, asterisk).
In view of the retention of the CDVs after detergent
treatment and its putative ER origin, we examined
whether other markers of the ER are resistant to Triton
extraction. After extraction of nontransfected cells, PDI
labeling was extensively reduced from the characteristic
ER network to sparse vesicular elements (not shown),
demonstrating the existence of detergent-resistant do-
mains of the ER in normal cells. When the same experi-
ment was performed in cavDGV-transfected cells, those
vesicles were strongly labeled with both cavDGV and PDI
(Fig. 5 f). Moreover, the size of the detergent resistant PDI
domain was increased, suggesting that the expression of
cavDGV induced the enlargement of the ER subdomain.
The cavDGV protein retains the putative intramembrane
domain of the wild-type protein, but caveolin has also
been suggested to exist in a soluble form (Uittenbogaard
et al., 1998). To examine whether cavDGV is membrane-
associated, transfected cells were treated with pH 11 so-
dium carbonate. The mutant protein, like the wild-type
protein in these cells, was resistant to carbonate treatment
(Fig. 5 i). However, in contrast to full-length caveolin, the
cavDGV mutant was soluble after extraction with detergent
in this biochemical assay. This contrasts with the lack of
extraction of the mutant protein in intact cells as judged by
immunofluorescence microscopy and suggests that the
protein is in a nonraft environment, but in the intact cell
this domain is retained through nonlipidic interactions.
CavDGV Associates with a Neutral Lipid-containing 
Organelle and Induces Lipid Accumulation 
CavDGV specifically inhibits H-ras function through an ef-
fect on cholesterol at the plasma membrane. Therefore, we
examined whether cavDGV had functional effects on lipid
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Figure 5. Biochemical and morphological characteriza-
tion of the CDV compartment. a, HA-tagged cavDGV
expressing cells were incubated in a medium containing
5 mg/ml of BFA for 4 h and were then labeled with a
polyclonal antibody to p23 (a cis Golgi marker) and an
mAb to the HA tag, followed by secondary antibodies
and finally incubated with DAPI to visualize the resis-
tant cells. BFA treatment induced a dramatic tubula-
tion of Golgi stacks (green), however CDV rings (red)
were completely resistant to the treatment. b and c,
HA-tagged cavDGV-transfected cells were incubated be-
fore fixation in a tris-buffered medium containing 1%
Triton X-100 at 48C for 3 min and were then fixed and
labeled with an mAb to b-tubulin and a polyclonal anti-
body to HA tag, followed for secondary antibodies and
DAPI to visualize the resistant cells. The CDV com-
partment (green) and the microtubule network (red)
were both resistant to the extraction with the detergent.
When the cells were pretreated in a medium containing
1.6 mM nocodazole for 4 h and were then extracted
with the detergent, the microtubule network appeared
completely disorganized in a very diffuse cytoplasmic
staining (compare c with b) but CDV rings remained
resistant to the detergent. d and e, Epon sections of de-
tergent extracted GFP-tagged cavDGV-transfected cells
were labeled with antibodies to GFP followed by pro-
tein A–gold before embedding. CavDGV was detected in
electron-dense aggregates (arrowheads) on the mem-
brane of CDV ring-shaped structures surrounded by a
network of intermediate filaments (arrows in d). Other
internal membranes like the nuclear envelope (arrows
in e) or mitochondrial membranes were solubilized.
The membranes of the rough ER did not contain
cavDGV (asterisk in d). f–h, CavDGV-transfected cells
were extracted with 1% Triton X-100 at 48C for 3 min
and were then labeled with an mAb to HA tag and a
polyclonal antibody to PDI. Some domains of the ER
were resistant to the extraction with detergents (h,
compare with Fig. 2 e) and clearly colocalized with
cavDGV. i, CavDGV-transfected cells were homogenized
at 48C in a Tris buffered solution or in Tris buffered so-
lution containing pH 11 0.5 M NaCO3 or 1% Triton
X-100. Then, a postnuclear supernatant of each treat-
ment was centrifuged at 75,000 rpm for 30 min to sepa-
rate membrane associated proteins (p75) or soluble
proteins (sol). 5 mg of protein of each sample were re-
solved by SDS PAGE electrophoresis, transferred to
p-immobilon membranes and the presence of HA, cav-1,
and PDI detected by Western blotting by means of spe-
cific antibodies. The three studied proteins were associ-
ated with the membrane fraction of the cells homoge-
nized in the control buffer and in the buffer containing
NaCO3. Although cav-1 was resistant to the solubiliza-
tion with 1% Triton, HA and PDI were solubilized.
Bars: (d and e) 100 nm; (a–c and f) 5 mm.
 o
n
 O
ctober 21, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published March 5, 2001
The Journal of Cell Biology, Volume 152, 2001 1066
Figure 6. CDV is a lipid-enriched compartment and cavDGV expression induces lipid accumulation. a–c, CavDGV HA-tagged transfected
cells were labeled with mAbs to HA, followed by Cy3-conjugated secondary antibodies. The samples were mounted in mowiol, contain-
ing a solution of the lipid probe, Nile red. The cells were selected for the presence of rings in the red channel and the corresponding im-
age in the green channel was captured. Then the samples were exposed for 30 s in the red channel before the corresponding image was
captured. Nile red staining was within the center of CDVs, whereas cavDGV formed the characteristic ring around the vesicle (arrow-
 o
n
 O
ctober 21, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published March 5, 2001
Pol et al. Caveolin Mutant Causes Cholesterol Disorder 1067
distribution. CavDGV-transfected cells were labeled with
the neutral lipid probe, Nile red. When cavDGV cells were
incubated with Nile red, the lipid marker accumulated in
late endosomes, colocalizing with LBPA (not shown), but
also in CDVs (Fig. 6 a). Close examination of the images
revealed that the Nile red staining was within the center of
the CDVs, whereas the caveolin mutant formed a charac-
teristic ring around the vesicle (Fig. 6 a, insert and arrow-
heads) entirely consistent with the electron microscopic
observations. The association of lipid droplets with a do-
main of the ER is consistent with recent studies in adipo-
cytes (Prattes et al., 2000). As shown in Fig. 6 c, cavDGV ex-
pression caused an increased intracellular accumulation of
lipids compared with nontransfected cells (Fig. 6, b and c),
demonstrating that cavDGV expression induces a lipid stor-
age disorder by accumulating neutral lipids inside the
CDVs (arrowheads) and in other intracellular compart-
ments (arrows). Although the intracellular accumulation
of lipids induced by cavDGV was variable, the mean in-
crease in Nile red staining in cavDGV-transfected cells was
over twofold higher than nontransfected cells (ratio of pix-
els in cavDGV-transfected/untransfected cells 5 2.22 6 0.89).
In contrast, full-length cav-3 caused no significant accumu-
lation of neutral lipids (ratio of cav-3-transfected/untrans-
fected cells 5 1.07 6 0.10). Together with the electron mi-
croscopic observations, these results strongly suggest that
the mutant caveolin protein specifically accumulates in the
membrane of lipid droplets and that the mutant protein in-
duces increased accumulation of neutral lipids.
CavDGV Inhibits the Post Late Endosomal Trafficking of 
Cholesterol and Reduces Cholesterol Efflux
and Synthesis 
As cavDGV causes intracellular accumulation of lipids and
functional studies suggest an effect on cholesterol, we next
investigated the effect of cavDGV expression on FC using
the fluorescent cholesterol probe, filipin. In control cells,
filipin labeling (which labels nonesterified FC) was found
in the Golgi/recycling endosome area, on the plasma mem-
brane, and in some scattered intracellular vesicles (Fig. 6,
d and k). However, after 24–32 h of the cavDGV expression
a dramatic change in the filipin labeling pattern was ob-
served: in 65% of cavDGV expressing cells, there was no de-
tectable filipin labeling on the plasma membrane (Fig. 6,
arrows), in 72% of the cells, cholesterol was accumulated
in very enlarged intracellular vesicles (Fig. 6, arrowheads)
identified as late endosomes for the presence of LBPA
(Fig. 6, g–j) and in 90% of the cells cholesterol was not
present in the perinuclear (Golgi/recycling endosome) re-
gion. Colocalization between cavDGV and filipin under
these conditions was rare, indicating that little FC is
present in cavDGV vesicles (Fig. 6, e and f, insert and k).
These results suggest that cavDGV promotes a similar lipid
storage disorder to that occurring in lipid storage diseases
in which FC accumulates in late endosomes (Kobayashi et
al., 1998). To further explore this, we biochemically mea-
sured the efflux of cellular cholesterol to serum acceptors
in cell cultures transfected with cavDGV. COS-1 cells were
transfected either with HA-tagged cavDGV or vector alone
and radiolabeled with[14C]cholesterol as detailed in Mate-
rials and Methods. Cholesterol efflux to 20% serum during
2 h was measured 48 h after transfection. A small but sig-
nificant reduction of 15% was observed in those cultures
expressing cavDGV, from 6.4 6 0.14 to 5.5 6 0.28 (% of
[14C]cholesterol efflux). Interestingly, although the efflux
of cholesterol was reduced, the total cholesterol content of
cavDGV expressing cells was identical to control cells (data
not shown). The level of cholesterol esterification was also
not significantly modified, and the ACAT inhibitor had no
effect on labeling of lipid-rich structures by the cavDGV
mutant (data not shown). In addition, cholesterol synthe-
sis was reduced by z30% (from 565 6 20 cpm/mg of pro-
tein in control cells to 384 6 109 in cavDGV cells, in three
independent experiments) suggesting that this decrease
may balance the decreased efflux. Taken together, we con-
clude that cavDGV expression has a small effect on FC ef-
flux but the major effect of the mutant protein is to induce
the redistribution of cellular cholesterol pools, from the
PM to late endosomes.
The decrease in plasma membrane FC and accumulation
of FC in late endosomes induced by expression of DGV
(24–32 h after transfection), is similar to that observed in a
number of lysosomal storage diseases such as NPC1 and
gangliosidoses (Kobayashi et al., 1998). This phenotype can
be mimicked experimentally using the drug U18666A, a hy-
drophobic amine that acts on negatively charged phospho-
lipids in the late endosomes and therefore causes late endo-
somal accumulation of FC (Kobayashi et al., 1998). Thus,
we speculated that the drug U18666A might mimic the ef-
fect of cavDGV on the cholesterol cycle. To test the syner-
gism between cavDGV expression and the U18666A drug,
the cells were transfected for different times with cavDGV in
the presence of U18666A and the cholesterol distribution
heads and merge panel). Cells expressing cavDGV showed a marked accumulation of lipids, in CDVs, and in other vesicular structures
(arrows in c), compared with nontransfected cells. d–f, CavDGV HA-tagged transfected cells were labeled with filipin (to visualize cellu-
lar FC, see Materials and Methods for details) and with an mAb to the HA tag. CavDGV expression induced a marked redistribution of
filipin: 65% of cavDGV expressing cells did not contain filipin on the PM (arrows in d and f) and in 72% of the transfected cells filipin was
detected in very enlarged cytoplasmic vesicles (arrowheads and insert f). g–j, CavDGV HA-tagged transfected cells were labeled with fil-
ipin (blue) and with antibodies to the HA tag (red) and to LBPA (green). CavDGV expression induced redistribution of FC to very en-
larged late endosomes (arrows in i and j). k–m, BHK were transfected with cavDGV in a normal medium (k) or in a medium containing
4.5 mg/ml of U18666A (l and m) for different times and cholesterol distribution was monitored by means of filipin. In cells expressing
cavDGV, a complete accumulation of lipids in late endosomes was evident after 24–32 h (k). However, in those cells expressing cav DGV in
the presence of U18666A the complete accumulation of FC in late endosomes was evident after 16 h (l), demonstrating that the combi-
nation of the drug and the cavDGV results in an earlier lysosomal storage disorder. Finally, after 24 h few differences could be observed
between nonexpressing and cavDGV expressing cells, but some very enlarged intracellular vesicles were present in transfected cells (ar-
rows in m). Bar, 5 mm.
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was monitored by means of filipin. In cells expressing
cavDGV, a complete accumulation of lipids in late endo-
somes was evident after just 16 h of the transfection and
U18666A treatment (Fig. 6 l) demonstrating that the com-
bination of the drug and the mutant results in an earlier ly-
sosomal storage disorder. After 24 h, the intracellular ac-
cumulation of filipin in nontransfected cells resembled
cavDGV expressing cells, but some characteristic enlarged
vesicles could be observed in transfected cells (Fig. 6 m, ar-
row). These results show that U18666A causes the accumu-
lation of FC in late endosomes in a synergistic manner with
the cavDGV mutant, suggesting that both treatments affect
different steps of the same transport pathway.
Full-length Caveolins and cavDGV Accumulate on Lipid 
Droplets Formed in Response to Oleic Acid Treatment 
To further investigate the association of full-length caveo-
lins with bona fide lipid droplets, cells were treated with
oleic acid (Brasaemle et al., 1997) to induce lipid droplet
accumulation. Untreated cells transfected with full-length
cav-3 HA showed some colocalization with Nile red, but
few large rings (only 10% of the cells contained evident
rings; Fig. 7 e). In contrast, 65% of cells transfected with
cav-3 YFP showed intracellular rings (Fig. 7 d). Cells were
then treated with oleic acid, which caused increased accu-
mulation of enlarged Nile red positive lipid droplets (see
example in Fig. 7 c). As expected, cavDGV was exclusively
detected surrounding the enlarged droplets (Fig. 7 a). In
addition, full-length cav-3 was now associated with the
droplets in the majority of oleic acid-treated cells (98% of
the cells transfected with YFP-tagged cav-3; 52% of cells
with HA-tagged cav-3), as well as showing plasma mem-
brane and Golgi complex labeling. Full-length VSVG-
tagged cav-1 distributed in a similar manner to HA-tagged
cav-3, although the accumulation on lipid droplets was less
evident. However, endogenous cav-1 was rarely observed
on rings even after the oleic acid treatment, although in
some cells (10%) it was observed in a very dotted and
weak pattern around some of the droplets (not shown). In
contrast, myc-tagged cav-2 showed a dramatic and com-
plete redistribution from the Golgi area in control cells
(Fig. 7 f) to the lipid droplets after oleic acid treatment
(Fig. 7 i).
Figure 7. Full-length caveo-
lins and cavDGV accumulate on
lipid droplets formed in re-
sponse to oleic acid treatment.
a–c, BHK cells preincubated in
a medium containing oleic acid
for 16 h, were transfected with
HA-tagged cavDGV, incubated
for an additional 24 h in a me-
dium containing oleic acid, la-
beled with antibodies to HA
tag and finally mounted in
mowiol containing Nile red
(see Materials and Methods
for details). CavDGV (b) was
exclusively detected surround-
ing very enlarged Nile red-pos-
itive lipid droplets (c). d–i, Un-
treated BHK (d, e, and f) or
cells preincubated in a me-
dium containing oleic acid for
16 h (g, h, and i) were trans-
fected with YFP-tagged cav-3
(d and g), HA-tagged cav-3 (e
and h), or myc-tagged cav-2 (f
and i) and incubated for an ad-
ditional 24 h in medium with
or without oleic acid. Cells
transfected with HA or myc
tag were labeled with specific
antibodies and cells trans-
fected with the YFP-tagged
constructs were mounted with-
out any additional manipula-
tion after fixation. 65% of cells
transfected with cav-3-YFP
showed, in addition to PM and
Golgi complex usual labeling,
some intracellular rings (d). In contrast, very few rings were observed in those cells transfected with HA-cav-3 (e). After oleic acid treat-
ment, in 98% of the cells transfected with YFP-tagged (g) or 52% of the cells transfected with HA-tagged cav-3 (h) the protein, in addi-
tion to the PM labeling, was observed on lipid droplets (Nile red staining not shown). Myc-tagged cav-2 showed a dramatic redistribu-
tion from the Golgi area in control cells (f) to the lipid droplets after oleic acid treatment (i). Bars, 5 mm.
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Discussion
Caveolin Mutants and Wild-type Caveolins Access 
Lipid-containing Bodies 
In the present study, we have shown that a caveolin mu-
tant, which disrupts specific signaling pathways, induces a
cholesterol trafficking defect in the expressing cells. The
cavDGV containing compartment (CDV) shows the charac-
teristics of lipid droplets, being large, nonacidic, spherical
structures that are labeled by the neutral lipid dye, Nile
red. We have shown by electron microscopy with three dif-
ferent techniques that a membrane surrounds the lipid
droplets and that this membrane contains the caveolin mu-
tant protein that behaves as an integral membrane protein
biochemically. Morphologically identical structures are
observed in nontransfected cells suggesting that they are
not generated exclusively by expression of the mutant pro-
tein. However, staining with a neutral lipid dye strongly
suggests that they are enlarged in the mutant-expressing
cells. The localization of a caveolin mutant to a lipid drop-
let associated with the ER implicates caveolin in lipid
transport to/from lipid droplets. The mutant may be accu-
mulating aberrantly in a transient station on the caveolin
cycling pathway. This hypothesis is supported by the fact
that cav-3DGV and fluorescent-tagged full-length caveolins
are efficiently targeted to enlarged lipid droplets induced
by oleic acid treatment. Importantly, these experiments
also demonstrate that cavDGV accumulates specifically on
preexisting lipid droplets rather than only inducing the
formation of new structures. Our studies also show that
expressed and epitope-tagged wild-type caveolins, al-
though predominantly associated with the plasma mem-
brane and Golgi complex, can also associate with lipid
droplets. Cav-2 showed a particular propensity for lipid
droplets as shown in oleic acid-treated cells. Further work
will be required to ascertain whether the ready visualiza-
tion of the tagged proteins in the lipid droplets, as com-
pared with the endogenous proteins, may simply reflect
the higher levels of the expressed proteins or the inaccessi-
bility of caveolin epitopes in specific compartments
(Luetterforst et al., 1999). Importantly, coimmunoprecipi-
tation experiments with antibodies to the epitope-tagged
cavDGV mutant show that the mutant protein associates
with both endogenous cav-1 and cav-2 (not shown).
Molecular Requirements for Targeting to CDVs
Our results suggest that the absence of the NH2 terminus
of caveolin causes association with lipid droplets and pos-
sibly disruption of exit from the ER. The localization of
the DGV mutants (cav-3DGV, cav-1DGI, and cav-2DKV) is
quite distinct from a shorter truncation mutant, cav-3NED
(residues from 33 to 151; see Luetterforst et al., 1999) or
cav-160-178 described recently as the equivalent truncation
of cav-3DGV for cav-1. Notice that since cav-1 is 27 residues
longer at the NH2 terminus than cav-3 (178 aa and 151 aa
respectively), the equivalent truncation for cav-3DGV in
cav-1 is the deletion of 81 residues of the NH2-terminal do-
main up to the scaffolding domain, referred as cav-1DGI in
this paper (Machleidt et al., 2000). The cavDGV mutants do
not label the plasma membrane and accumulate in the
CDVs, whereas cavNED labels the Golgi complex and cell
surface in a similar manner to the wild-type protein or the
cav-160-178. This suggests that the region between residues
33 and 53 is of critical importance in attaining its steady
state distribution and perhaps in exit from the CDVs/ER
lipid droplets. The inability to move out of this compart-
ment may lead to the phenotypic changes described here.
The 21 residues sequence (NEDIVKVDFEDVIAEPEG-
TYS) shows very high homology to the same region of
cav-1 and cav-2 and the nine central residues are almost
identical in all three caveolin members. Because all three
caveolin members can access the DGV compartment, it
will be of great interest to ascertain whether specific pro-
teins can bind to cavNED, but not cavDGV. In addition, be-
cause this region mediates the oligomerization of caveo-
lins (Sargiacomo et al., 1995) it will be important to
elucidate if oligomerization is necessary for the exit from
the ER. The conserved scaffolding domain of caveolin is
not necessary for targeting caveolins to CDVs as the cavLLS
mutant (residues from 75 to 151) shows a similar accumu-
lation to cavDGV (this study) and also is a potent and spe-
cific inhibitor of H-ras mediated Raf activation (Pol, A.,
and R.G. Parton, manuscript in preparation) presumably
by a similar mechanism to cavDGV (Roy et al., 1999).
The Caveolin Cycle and Cholesterol Balance
Expression of the cavDGV mutant causes increased intra-
cellular accumulation of FC and a decrease in plasma
membrane FC as judged by filipin staining. This is consis-
tent with previous studies showing that expression of
cavDGV inhibits Raf-mediated H-Ras activation and that
this inhibition could be mimicked by cholesterol depletion
and rescued by cholesterol readdition (Roy et al., 1999). A
striking effect of cavDGV is the accumulation of FC intra-
cellularly within enlarged late endosomes and therefore
the phenotype of the mutant-expressing cells appears simi-
lar to the well-characterized phenotype of NPC12/2 cells.
Consistent with this hypothesis, a recent study suggested
that NPC12/2 neurons are unable to respond to the neu-
rotrophin, BDNF (Henderson et al., 2000). The link be-
tween the cavDGV phenotype and cholesterol disorders
is further strengthened by the finding that the drug
U18666A mimics the NPC12/2 and the DGV phenotype
causing the accumulation of FC in late endosomes.
U18666A is thought to act at the level of the late endo-
somes/lysosomes to alter the flow of cholesterol between
internal pools and recent evidence suggests that the NPC1
protein and U18666A work in a similar transport step
(Lange et al., 2000). In contrast to the phenotype of
NPC12/2 fibroblasts, the cavDGV mutant had no effect on
cholesterol esterification but did cause a small decrease in
both cholesterol efflux and cholesterol biosynthesis. The
net result of these changes was that there was no major
change in total cellular cholesterol levels in the cavDGV-
expressing cells.
In conclusion, our studies raise the possibility that cave-
olin play a role in trafficking of lipids to/from lipid drop-
lets. Whether caveolin cycles through this compartment
under physiological conditions requires further investiga-
tion, but our studies suggest that lipid droplet formation in
response to oleic acid and cholesterol manipulation causes
wild-type caveolin to accumulate in these structures (Pol,
A., and R.G. Parton, unpublished information). The stud-
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ies presented here identify the underlying defect in cells
expressing a caveolin dominant negative mutant as a lipid
transport defect and strongly implicate caveolins in lipid
transport. They also provide new tools to dissect the cru-
cial role of lipid transport in diverse cellular processes and
to understand the role of caveolins in cell physiology.
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